A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Completed

• Conditions: Leukemia, Myeloid

• Registration Number: NCT04598789
• Lead Sponsor: Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Brief Summary

The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-07
• Study First Submitted: 2020-10-16
• Study First Submitted QC: 2020-10-16
• Study First Posted: 2020-10-22
• Primary Completion: 2021-06-30
• Study Completion: 2021-09-01
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-24
• Last Update Posted: 2021-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 61

Inclusion Criteria

• children and adults)
• HSCT from a one-antigen mismatch unrelated donors
• Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017

Exclusion Criteria

none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
acute GvHD incidence	2012-2017

Trial Locations

Locations (1)

AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita; 🇮🇹 Turin, Italy